Iovance Biotherapeutics (IOVA) said late Monday that Health Canada has issued a notice of compliance with conditions for Amtagvi to treat adult patients with advanced melanoma.
The company said the market authorization is conditional, pending the results of trials to confirm its clinical benefit.
Iovance shares were up about 4% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.